Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | TACR3 | P29371 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450839 | 0.92 | KMT2A (0.55) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1451384 | 0.92 | KMT2A (0.53) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1450101 | 0.90 | KMT2A (0.67) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1450641 | 0.89 | KMT2A (0.52) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1450710 | 0.89 | KMT2A (0.57) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1450740 | 0.88 | KMT2A (0.50) | KMT2AMEN1HTR2AHTR2CSLC6A4 | |
| SCHEMBL1451376 | 0.87 | KMT2A (0.56) | KMT2AMEN1TACR3LMNAALDH1A1 | |
| SCHEMBL1450406 | 0.87 | KMT2A (0.55) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1450650 | 0.87 | BRD4 (0.49) | KMT2AMEN1TACR3HTR2AHTR2C | |
| SCHEMBL1451399 | 0.86 | KMT2A (0.48) | KMT2AMEN1TACR3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167487-B1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2015-02-18 | — | — | EP | claimed |
| US-7910576-B2 | Pyrrole derivatives as P2Y12 antagonists | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | claimed |
| US-20100226918-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-09-09 | — | — | US | claimed |
| EP-2167487-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-03-31 | — | — | EP | claimed |
| WO-2008155022-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-2167487-B1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2167487-B1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2015-02-18 | — | — | EP | disclosed |
| US-7910576-B2 | Pyrrole derivatives as P2Y12 antagonists | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| US-7910576-B2 | Pyrrole derivatives as P2Y12 antagonists | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| US-7910576-B2 | Pyrrole derivatives as P2Y12 antagonists | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| US-20100226918-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-09-09 | — | — | US | disclosed |
| US-20100226918-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-09-09 | — | — | US | disclosed |
| US-20100226918-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-09-09 | — | — | US | disclosed |
| WO-2008155022-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226918-A1 | PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY13 | KMT2A 4670/4885MEN1 3103/4885TACR3 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.